Travis Steed
Stock Analyst at B of A Securities
(2.74)
# 2,087
Out of 5,090 analysts
87
Total ratings
44.93%
Success rate
6.64%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MASI Masimo | Initiates: Neutral | $162 | $141.68 | +14.34% | 1 | Nov 17, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $279 → $261 | $193.96 | +34.56% | 9 | Apr 7, 2025 | |
| PEN Penumbra | Initiates: Buy | $320 | $300.66 | +6.43% | 1 | Mar 14, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $125.08 | +19.92% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $85.43 | -0.50% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $86.19 | +4.42% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $19.72 | +62.27% | 1 | Nov 5, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $18.54 | +142.72% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $480 → $45 | $4.39 | +925.06% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $364.02 | -13.47% | 5 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $295 | $304.49 | -3.12% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $33.32 | -51.98% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $33 | $20.92 | +57.74% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $94.28 | +69.71% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $575.34 | -45.25% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $2.01 | +298.01% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $11.69 | +113.86% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $14.42 | +489.46% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $65.49 | +90.87% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $101.36 | +43.05% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $97.52 | -47.70% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $175 | $40.07 | +336.74% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $13.23 | +308.16% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $63.30 | -65.24% | 1 | Jul 17, 2017 |
Masimo
Nov 17, 2025
Initiates: Neutral
Price Target: $162
Current: $141.68
Upside: +14.34%
Becton, Dickinson and Company
Apr 7, 2025
Maintains: Overweight
Price Target: $279 → $261
Current: $193.96
Upside: +34.56%
Penumbra
Mar 14, 2025
Initiates: Buy
Price Target: $320
Current: $300.66
Upside: +6.43%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $125.08
Upside: +19.92%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $85.43
Upside: -0.50%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $86.19
Upside: +4.42%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $19.72
Upside: +62.27%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $18.54
Upside: +142.72%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $4.39
Upside: +925.06%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $364.02
Upside: -13.47%
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $304.49
Upside: -3.12%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $33.32
Upside: -51.98%
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $20.92
Upside: +57.74%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $94.28
Upside: +69.71%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $575.34
Upside: -45.25%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $2.01
Upside: +298.01%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $11.69
Upside: +113.86%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $14.42
Upside: +489.46%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $65.49
Upside: +90.87%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $101.36
Upside: +43.05%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $97.52
Upside: -47.70%
May 25, 2021
Initiates: Overweight
Price Target: $175
Current: $40.07
Upside: +336.74%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $13.23
Upside: +308.16%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $63.30
Upside: -65.24%